ESMO 2024 | Kidney cancer at ESMO 2024: CONTACT-03, TiNivo-2 and SUNNIFORECAST
Ignacio Duran, MD, PhD, Hospital Universitario Marques de Valdecilla, Santander, Spain, comments on recent kidney cancer research presented at the European Society for Medical Oncology (ESMO) 2024 Congress. The CONTACT-03 (NCT04338269) and TiNivo-2 (NCT04987203) trials, both investigating checkpoint inhibitor sequencing in metastatic kidney cancer, found no benefit in progression-free or overall survival, indicating that re-sequencing checkpoint inhibitors does not improve outcomes. The SUNNIFORECAST study (NCT03075423) highlights potential benefits of nivolumab and ipilimumab in non-clear cell renal cell carcinoma (RCC) compared to tyrosine kinase inhibitors. Additional trials such as LITESPARK-005 (NCT04195750) explored belzutifan, and preliminary data on microbiota-based interventions suggest potential enhancements to checkpoint inhibitor responses. This interview took place at the ESMO 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
